Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 205

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 205
---
 In addition, our Board has the ability to intervene in instances where actions by our executive officers vis-à-vis Company performance objective attainment would be considered unduly risky to prevent or penalize such actions. Compensation Committee Report The Compensation Committee of the Company has reviewed and discussed with management the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K. Based on this review and discussion, the Compensation Committee recommended to our Board that the foregoing Compensation Discussion and Analysis be included in this proxy statement. Submitted by the Compensation Committee of the Board of Directors Michael Perry, Committee Chair Hongbo Lu William Waddill Compensation Committee Interlocks and Insider Participation During fiscal year 2024, Mr. Waddill, Dr. Ferrari, and Dr. Perry, served on the Compensation Committee. During fiscal year 2024 and through December 2024, there were no compensation committee interlocks between the Company and other entities involving the Company’s executive officers and directors. For information regarding a transaction involving the brother of Dr. Douglass Given, the Company's former Director and Chairman of the Board,which is required to be disclosed under Item 404 of Regulation S-K, see “Certain Relationships and Related Transactions, and Director Independence” below. Table of Contents 2025 PROXY STATEMENT Executive Compensation 43

Fiscal 2024 Summary Compensation Table The following table summarizes compensation earned for services rendered during fiscal 2024, 2023, and 2022 by our Chief Executive Officer, our Chief Financial Officer, our Chief Operating Officer and General Counsel, our Chief of Discovery and Translational Medicine, and our former Chief Medical Officer and former Chief Commercial Officer, collectively our “Named Executive Officers”: Name and Principal Position Year Salary ($) Bonus (S) Stock Awards (1) ($) Non-Equity Incentive Plan Compensation (2) ($) All Other Compensati on (3) ($) Total ($) Christopher Anzalone 2024 951,012 — 10,319,000 (4) 1,152,000 1,461 12,423,473 President and Chief Executive Officer 2023 902,522 — 8,314,056 (5) 700,000 1,515 9,918,093 2022 863,417 — 10,382,549 (7) 783,315 (6) 2,688 12,031,969 Kenneth Myszkowski 2024 592,369 — 2,589,750 314,